Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States

被引：0
|
作者：
Shujing Zhang
Arielle G. Bensimon
Ruifeng Xu
Ruixuan Jiang
Alexandra Greatsinger
Adina Zhang
Mizuho Fukunaga-Kalabis
Clemens Krepler
机构：
[1] Merck & Co.,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adjuvant treatment; Cost-effectiveness analysis; Pembrolizumab; Stage IIB–IIC melanoma; US health sector perspective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3038 / 3055
页数：17
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
    Zhang, Shujing
    Bensimon, Arielle G.
    Xu, Ruifeng
    Jiang, Ruixuan
    Greatsinger, Alexandra
    Zhang, Adina
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    ADVANCES IN THERAPY, 2023, 40 (07) : 3038 - 3055
  • [2] Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland
    Favre-Bulle, Andrea
    Bencina, Goran
    Zhang, Shujing
    Jiang, Ruixuan
    Andritschke, Daniel
    Bhadhuri, Arjun
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 283 - 292
  • [3] Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
    Bensimon, Arielle G.
    Zhou, Zheng-Yi
    Jenkins, Madeline
    Song, Yan
    Gao, Wei
    Signorovitch, James
    Krepler, Clemens
    Liu, Frank Xiaoqing
    Wang, Jingshu
    Aguiar-Ibanez, Raquel
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 981 - 993
  • [4] Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma
    Rutkowski, Piotr
    Czarnecka, Anna M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (09) : 897 - 902
  • [5] Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States
    Lai, Yizhen
    Bensimon, Arielle G.
    Gao, Emily
    Bhattacharya, Rituparna
    Xu, Ruifeng
    Chevure, Jestinah
    Imai, Kentaro
    Haas, Naomi B.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : 612.e1 - 612.e11
  • [6] Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection
    Lopez-Vinueza, Cesar
    Urrego-Reyes, Juan
    Gutierrez, Fredy R. S.
    Wurcel, Victoria
    Zhang, Shujing
    Jiang, Shan
    Jiang, Ruixuan
    Harvey, Angela Zambrano
    Dhankhar, Praveen
    Sawhney, Baanie
    Baluni, Gargi
    Jain, Shrishti
    Bhadra, Debosmita
    ADVANCES IN THERAPY, 2023, 40 (06) : 2836 - 2854
  • [7] Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection
    Cesar Lopez-Vinueza
    Juan Urrego-Reyes
    Fredy R. S. Gutierrez
    Victoria Wurcel
    Shujing Zhang
    Shan Jiang
    Ruixuan Jiang
    Angela Zambrano Harvey
    Praveen Dhankhar
    Baanie Sawhney
    Gargi Baluni
    Shrishti Jain
    Debosmita Bhadra
    Advances in Therapy, 2023, 40 : 2836 - 2854
  • [8] Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in Mexico
    Wurcel, Victoria
    Rojas Rojas, Monica
    Urrego-Reyes, Juan
    Rivera, Daniela Medrano
    Acevedo, Roberto
    Jiang, Ruixuan
    Jiang, Shan
    Zhang, Shujing
    Caparros, Alfredo
    Krepler, Clemens
    Fukunaga-Kalabis, Mizuho
    Younan, Nadine D.
    Alexander, Deepak
    Hughes, Robert
    Weston, Georgie
    JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 346 - 353
  • [9] Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
    Tian, Wentao
    Niu, Lishui
    Wang, Ziqi
    Lu, Ruoyu
    Xiao, Gang
    Deng, Fuxing
    Tanzhu, Guilong
    Zhou, Rongrong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [10] Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina
    Victoria Wurcel
    Emilie Scherrer
    Raquel Aguiar-Ibanez
    Juan Ignacio Altuna
    Fernando Carabajal
    Shrishti Jain
    Gargi Baluni
    Oncology and Therapy, 2021, 9 : 167 - 185
12345